BAM Logo

Biotherapy : Vedolizumab

[Biotherapie : Vedolizumab]

EPTIS factsheet 1051029 | Last revision 2023-05-24 | URL: https://www.eptis.bam.de/pts1051029 https://www.eptis.bam.de/pts1051029

PT provider
PT provider CTCB CTCB
Based in France
Language(s) English /French
Remarks All our biotherapy programs include a clinical case to interpret
Product groups Health care / medical devices
Testing fields Medical analysis
Technical details
Test item Tested property Testing method
human serum Quantification of Infliximab serum concentrations all methods
Anti-Infliximab antibodies detection and quantification all methods
Aims of the PT scheme
Target group of participants merdical laboratories / no restriction to participation but possible extra charges according to the country
Linked to specific legislation / standards no
Additional, subsidiary aims
Number of participants 13
Accredited or otherwise reviewed by a 3rd party

Accredited by none on the basis of


Operation is commissioned / requested by no
Fees and frequency
Participation fee 462 euros
Regularly operated Yes (3 surveys per year (one sample per survey))
Year of first operation 2020
Contact details of the PT provider
Provider Contact person
33 route de Bayonne

Phone: +33 (0)5 34 51 49 80
Fax: +33 (0)1 57 67 25 90
Web: https://www.ctcb.com/ https://www.ctcb.com/
Dr Stéphanie Albarede
Phone: +33 (0)5 34 51 49 80
Fax: +33 (0)1 57 67 25 90
Email: s.albarede@ctcb.com s.albarede@ctcb.com
If you find any mistakes please contact the responsible EPTIS coordinator in France, Mr Patrick Bironneau. Mr Patrick Bironneau.
Any questions or problems? Please contact us at eptis@bam.de.
Application version: 1.23-SNAPSHOT.20230502124635-7925ae379a631fc1ececff45d2921c8db38877d5